Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, has received a US$3 million investment from China’s Guangxi Wuzhou Pharmaceutical Group.

The funds raised will be used to advance Integra Holdings’ existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.

Integra Holdings, founded by Yissum in 2012, has a portfolio of companies in such therapeutic areas such as oncology, Alzheimer’s disease, infectious diseases, analgesia and inflammation. The innovative products developed by the portfolio companies range in maturity from pre-clinical stages of development, through clinical stages, to registration. Currently, the portfolio includes Ayana, Atox Bio, Avraham Pharmaceuticals, Lipomedix, Tiltan Pharma, Lipocure and HIL Applied Medical, in addition to two new companies, which are now being established and develop products with expected short time to market.

Investors in Integra Holdings are Invatech Holdings, a group of private US and Israeli investors; Halman-Aldubi Provident and Pension Fund; the Funds of Teaching Personnel and the HUJI Provident Fund. Integra Holdings has raised a total of US$12 million to date.